Organogenesis (ORGO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ORGO · Stock Price

USD 2.53-0.53 (-17.32%)

Market Cap: $292.7M

Historical price data

Market Cap: $292.7MPipeline: 4 drugs (2 Phase 3)Founded: 1985HQ: Canton, United States

Sector Ranking#22 in Regenerative Medicine #51 in Cell & Gene Therapy

Overview

Organogenesis's mission is to empower healing by delivering regenerative tissue innovations. The company has achieved significant milestones, including receiving one of the first FDA approvals for a living, human-cell-based product (Apligraf®) and building a leading portfolio of commercial products for advanced wound care and surgical biologics. Its strategy focuses on leveraging its foundational 3D cell delivery platform, expanding manufacturing capacity, and supporting patients through comprehensive access programs to drive growth in the regenerative medicine market.

Advanced Wound CareSurgical BiologicsSports Medicine

Technology Platform

Pioneering platform for delivering living cells via three-dimensional (3D) constructs to stimulate the body's innate healing and regeneration processes.

Pipeline

4

4 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Amniotic Suspension Allograft + Placebo	Knee Osteoarthritis	Phase 3
Amniotic Suspension Allograft + Placebo	Knee Osteoarthritis	Phase 3
Gintuit	Edentulous Alveolar Ridge	Phase 1/2
CelTx™	Gingival Recession	Pre-clinical

Funding History

3

Total raised:$220M

Debt$100MMidCap FinancialJun 15, 2018

IPO$70MUndisclosedNov 3, 2016

Private Equity$50MMorgan Stanley Private EquityJun 15, 2006

Opportunities

The company is positioned to capitalize on the growing global advanced wound care market, driven by aging demographics and rising diabetes rates.

Expansion of its surgical biologics portfolio and new manufacturing capacity in Rhode Island provide avenues for revenue growth and operational scaling.

Risk Factors

Key risks include dependence on favorable U.S.

reimbursement policies, intense competition in wound care leading to pricing pressure, and the operational complexity and regulatory scrutiny associated with manufacturing living cell-based products.

Competitive Landscape

Organogenesis competes with large medtech firms in advanced wound care (e.g., 3M, Smith & Nephew) and specialized regenerative medicine companies (e.g., MiMedx). Its competitive edge lies in its pioneering cell-based technology, comprehensive commercial portfolio, and deep reimbursement and patient support infrastructure.